RPL554 suspension
Sponsors
Verona Pharma plc
Conditions
COPD
Phase 2
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
CompletedNCT03443414
Start: 2017-06-01End: 2018-02-07Updated: 2019-06-04
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
CompletedNCT03673670
Start: 2018-07-16End: 2018-11-13Updated: 2019-10-10